吉非贝齐治疗高脂血症：一项开放性单盲试验。
Gemfibrozil in hyperlipidaemia: an open, single blind trial.
作者信息
Varthakavi P K, Turakhia D P, Sharma S S, Salgaonkar D S, Nihalani K D, Joshi V R
机构信息
Department of Cardiology, T.N. Medical College, Bombay.
出版信息
J Assoc Physicians India. 1990 Feb;38(2):136-40.
The efficacy of Gemfibrozil on S. lipid levels was studied in 36 middle aged subjects with type IIA, IIB, IV hyperlipidemia. Gemfibrozil was well tolerated in the dose of 1200 mg/day and no dropouts were attributable to its use. An overall reduction in total cholesterol (39.91%), total triglycerides (71.10%), VLDL triglycerides (62.97%). LDL cholesterol (45.57%) and apolipoprotein B levels (26.83%) were observed at 24 weeks. At the same time HDL cholesterol, and apolipoprotein A levels showed increases by 26.23% and 53.67% respectively. It is concluded that Gemfibrozil is an effective lipid lowering agent. Further long term studies are necessary to determine its optimal dosage and its long term safety in Indian subjects.
在36名患有IIA型、IIB型、IV型高脂血症的中年受试者中研究了吉非贝齐对血脂水平的疗效。吉非贝齐在1200毫克/天的剂量下耐受性良好，且未出现因使用该药而导致的受试者退出试验的情况。在24周时观察到总胆固醇总体降低了39.91%，总甘油三酯降低了71.10%，极低密度脂蛋白甘油三酯降低了62.97%，低密度脂蛋白胆固醇降低了45.57%，载脂蛋白B水平降低了26.83%。与此同时，高密度脂蛋白胆固醇和载脂蛋白A水平分别升高了26.23%和53.67%。得出的结论是，吉非贝齐是一种有效的降脂药物。有必要进行进一步的长期研究，以确定其在印度受试者中的最佳剂量及其长期安全性。
Zotero 插件